ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Sacubitril/valsartan as a modulator of pulmonary fibrosis: insights into Lnc-SNHG-16/miR-455 modulation and Notch/Smad-3 pathway inhibition.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis is a progressive and life-threatening interstitial lung disease marked by excessive extracellular matrix accumulation and declining pulmonary function. Despite available therapies, clinical outcomes remain suboptimal, necessitating the exploration of novel therapeutic approaches. Sacubitril/valsartan, a dual-acting agent combining a neprilysin inhibitor and angiotensin II receptor blocker, has recently emerged as a candidate with potential anti-fibrotic properties. This study investigates the therapeutic efficacy of sacubitril/valsartan in a bleomycin-induced rat model of pulmonary fibrosis. The compound was administered orally once daily, beginning on the first day of fibrosis induction and continued for 21 days. Fibrotic progression was evaluated through biochemical and histological assessments, including quantification of hydroxyproline content, α-smooth muscle actin (α-SMA) expression, collagen deposition percentage, and histopathological examination of lung tissue. Molecular analyses revealed that sacubitril/valsartan significantly downregulated the expression of long non-coding RNA SNHG-16 and concurrently upregulated miR-455 levels. These changes were associated with suppression of the Notch-2/Smad-3 signaling pathway. Additionally, sacubitril/valsartan treatment resulted in a notable reduction in pulmonary levels of transforming growth factor-β (TGF-β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), indicating attenuation of both fibrotic and inflammatory responses. Collectively, these findings suggest that sacubitril/valsartan mitigates pulmonary fibrosis through modulation of the SNHG-16/miR-455 axis and inhibition of the Notch-2/Smad-3/TGF-β signaling cascade, highlighting its potential as a promising therapeutic strategy for the management of pulmonary fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.